Actavis Pharma, Inc. received FDA approval for its generic glipizide oral tablet, positioning the company to enter the competitive oral anti-diabetic market segment. The clearance is expected to drive market share gains by offering a lower-cost alternative, thereby pressuring the pricing power of the branded leader.